RASAL2: wrestling in the combat of Ras activation

Abstract

Oncogenic activation of Ras proteins due to missense mutations is frequently detected in human cancers but rarely in breast cancer. In this issue of Cancer Cell, McLaughlin and colleagues report that ablation of the GasGAP gene, RASAL2, is an alternative mechanism by which Ras becomes activated in breast cancer.